AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$SCYX

SCYNEXIS, Inc. (SCYX) Reports Phase 1 Safety for SCY-770; Phase 2 Start Planned Q4 2026

SCYNEXIS reported that SCY-770 was well tolerated in a Phase 1 study, supporting dose selection. The company plans to start a Phase 2 trial for ADPKD in Q4 2026. According to the company, this is an early clinical de-risking step.

Original reporting
tradingview.com
Published Oct 6, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SCYNEXIS, Inc. (SCYX) Reports Phase 1 Safety for SCY-770; Phase 2 Start Planned Q4 2026 — source image
Source · tradingview.com
Decision brief

The 30-second read

$SCYXBullishMed
01

Why it matters

The Phase 1 safety readout de‑risks the program and could attract partnership or financing interest.

02

Market read

Early‑stage data often moves small‑cap biotech stocks; investors may position ahead of the upcoming Phase 2 start.

03

What to watch

Funding requirements for Phase 2 and competitive pipeline risks.

Relevance 8/10Novelty 8/10Timing: today

Background

SCYNEXIS is a clinical‑stage biotech focused on rare kidney disease therapies.

Company-level read

Ticker impact

$SCYXBullishHigh confidence
Context

SCYNEXIS reported positive Phase 1 safety data for its drug candidate SCY-770, a new clinical milestone.

Expected impact

potential upside as investors price in reduced clinical risk

Evidence & confidence

First disclosure of safety results; market typically reacts positively to favorable early‑stage data.

Market effects

Sector

May lift sentiment for the broader ADPKD therapeutic space.

Regional

Limited to US biotech investors.

Global

Low global impact beyond niche biotech sector.

Counterpoint

What could challenge this read

If Phase 2 fails to show efficacy, the early safety win may be priced out quickly.

Key entities

  • company
    SCYNEXIS, Inc.

    Biotech developer of SCY-770 for ADPKD.

Read at source← All news

Related articles

OCT 6
$SCYXHighAI 8/10

SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug

SCYNEXIS Inc. (SCYX) reported positive Phase 1 results for SCY-770, a drug for autosomal dominant polycystic kidney disease (ADPKD). The study showed favorable safety and tolerability across all doses. The company plans to start a Phase 2 study in Q4 2026. SCY-770 has FDA Orphan Drug Designation. SCYX shares closed at $5.03 on Monday, up 2.19% in premarket trading.

rttnews.com2 min
OCT 6
$SCYXMedAI 8/10

SCYNEXIS completes phase 1 study of SCY-770 for kidney disease

SCYNEXIS Inc. completed a Phase 1 study of SCY-770, an oral AMPK activator for Autosomal Dominant Polycystic Kidney Disease. The study enrolled 25 healthy participants and found the drug well-tolerated. SCY-770 has Orphan Drug Designation and will advance to a Phase 2 trial in Q4 2026. The drug has been evaluated in 300 participants across multiple trials. The condition has one approved therapy, Jynarque, with $1.5B in 2024 U.S. sales.

investing.com2 min
OCT 6
$SCYXMedAI 8/10

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS (SCYX) reported positive Phase 1 results for SCY-770, a potential first-in-class oral direct AMPK activator for ADPKD. The study showed favorable safety and tolerability, with Phase 2 initiation on track for Q4 2026. SCY-770 has Orphan Drug Designation from the FDA.

globenewswire.com2 min
SEP 28
$SCYXHighAI 8/10

Scynexis stock surges on $214M BARDA contract for SCY-247

Scynexis Inc (SCYX) shares rose 10% premarket after securing a $214M contract from BARDA for SCY-247, a treatment for invasive candidiasis. The deal includes $18.5M for Phase 2 trials. SCY-247 has FDA designations and positive Phase 1 data. The company expects to fund its share of costs within its existing plan. SCYX does not anticipate changes to its guidance for SCY-770 or its cash runway into 2029.

investing.com2 min